Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane ...

Early calls, unexpected plans and moments you can’t plan are part of everyday living: and modern beauty should keep up. With ...

Galderma (SIX: GALD), the pure-play dermatology category leader, has launched ‘Wake Up To Restylane’, a global campaign that showcases Restylane as an everyday beauty ally. Aligned with the growing ...

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it presented new data from its Injectable Aesthetics portfolio and pipeline at the American Society for ...

Galderma (SIX: GALD) will present nine abstracts at the Aesthetic & Anti‑Aging Medicine (AMWC) World Congress 2026 in Monaco, showcasing innovative and robust scientific data across its aesthetics ...

Galderma (SIX: GALD), the pure-play dermatology category leader, has announced the launch of Restylane Defyne and Restylane Refyne: the first OBT‑based hyaluronic acid injectables ever authorized in ...

Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA ® lidocaine range of Restylane ...

Ongoing clinical evidence continues to reinforce Restylane’s ability to deliver natural-looking, long-lasting results across multiple indications. 8-11 New clinical data presented at IMCAS ...

Food and Drug Administration (FDA) has approved Restylane Contour* for the correction of temple hollowing, expanding its use beyond cheek augmentation and midface contour ...